Skip to Content
Merck
CN

PZ0118

Nafoxidine hydrochloride

≥98% (HPLC)

Synonym(s):

1-[2-[4-(3,4-dihydro-6-methoxy-2-phenyl-1-naphthalenyl)phenoxy]ethyl]-pyrrolidine hydrochloride, CP-5600, Nafoxidene hydrochloride, PNU-0011100

Sign In to View Organizational & Contract Pricing.

Select a Size


About This Item

Empirical Formula (Hill Notation):
C29H31NO2 · HCl
CAS Number:
Molecular Weight:
462.02
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
51111800
MDL number:
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Nafoxidine hydrochloride, ≥98% (HPLC)

InChI key

HJOOGTROABIIIU-UHFFFAOYSA-N

SMILES string

Cl.COc1ccc2c(CCC(c3ccccc3)=C2c4ccc(OCCN5CCCC5)cc4)c1

InChI

1S/C29H31NO2.ClH/c1-31-26-14-16-28-24(21-26)11-15-27(22-7-3-2-4-8-22)29(28)23-9-12-25(13-10-23)32-20-19-30-17-5-6-18-30;/h2-4,7-10,12-14,16,21H,5-6,11,15,17-20H2,1H3;1H

assay

≥98% (HPLC)

form

powder

color

white to tan

solubility

H2O: ≥8 mg/mL

storage temp.

room temp

Quality Level

Biochem/physiol Actions

Estrogen receptor antagonist; anti-proliferative; non-steroidal antiestrogen; derivative of Tamoxifen
Nafoxidine is a potent estrogen receptor antagonist that exhibits anti-proliferative properties. It is a non-steroidal antiestrogen, a derivative of Tamoxifen.

pictograms

Health hazardExclamation mark

signalword

Warning

Hazard Classifications

Acute Tox. 4 Dermal - Acute Tox. 4 Oral - Carc. 2

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

R N Trivedi et al.
Contraception, 51(6), 367-379 (1995-06-01)
Time-related estrogen antagonistic action of a single oral contraceptive (1.25 mg/kg) dose of the triphenylethylene antiestrogen centchroman was determined in ovariectomized immature rats. Tamoxifen and nafoxidine were used for comparison. A single oral administration of centchroman followed by three doses
Ruria Namba et al.
Breast cancer research : BCR, 7(6), R881-R889 (2005-11-11)
Ductal carcinoma in situ (DCIS) is a noninvasive premalignant lesion and is considered a precursor to invasive carcinoma. DCIS accounts for nearly 20% of newly diagnosed breast cancer, but the lack of experimentally amenable in vivo DCIS models hinders the
Y S Lee et al.
Cancer letters, 110(1-2), 243-248 (1996-12-20)
The possible interaction between antiestrogens (tamoxifen, clomiphene and nafoxidine) and bepridil, a known Na+-Ca2+ exchange blocker, in the regulation of cell growth was investigated using U-373 MG human astrocytoma and SK-N-MC human neuroblastoma cells as model cellular systems. The co-treatment
M S Wisel et al.
International journal of fertility and menopausal studies, 39(3), 156-163 (1994-05-01)
To compare effects of various anti-estrogens on early pregnancy. Fifty regularly cycling guinea pigs were divided into five groups (five animals/group), of which three groups received 3 mg/kg body weight Nafoxidine, Centchroman, or Tamoxifen, respectively, on the 1st, 2nd, or
Tamar Hayon et al.
Cancer detection and prevention, 27(5), 389-396 (2003-10-31)
The antileukemic activity of nonsteroidal antiestrogens was investigated. Tamoxifen, clomiphene and nafoxidine caused a decrease in viability of the estrogen receptor-negative T-lymphoblastic leukemia cell line CCRF/CEM, nafoxidine being the most active. A combination of clomiphene and genistein resulted in a

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service